Insmed Incorporated is a global biopharmaceutical company. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 98.69% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 606.42M.
Undervalued
The company’s latest PE is -17.96, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 226.45M shares, decreasing 3.77% quarter-over-quarter.
Held by Stanley Druckenmiller
Star Investor Stanley Druckenmiller holds 1.77M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.74.